A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting

Phase 2

UBT251A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Sponsor:

Novo Nordisk A/S

Code:

NCT07668388

Conditions

Diabetes Mellitus, Type 2

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

UBT251

UBT251 Placebo

Semaglutide

Semaglutide Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-28. This information was provided to ClinicalTrials.gov by Novo Nordisk A/S on 2026-07-14.